Showing results for "Advaxis"
business
Bay State Biotech Report: Advaxis and Cervical CancerBloomberg biotech reporter Doni Bloomfield spoke with Advaxis CEO Daniel O’Connor about the company’s drug to treat recurrent carcinoma of the cervix by using a tweaked bacteria to awaken the immune system. That’s all on the Bay State Biotech Report, where Bloomberg biotechnology reporter Doni Bloomfield and Boston radio host Anne Mostue discuss the latest in biotech news from the Boston area and across the nation.March 16, 2017
business
U.S. EQUITY MOVERS: CLD CLDX CLVS HERO JPST MRTX NES OMG SINAAdvancers include: OMG +28.1%; To Be Bought by Apollo for $34/Shr, Premium 28% SINA +14.1%; In Pact With CEO for $456m Cash Investment TAOM +13.7%; Gets ‘Going Private’ Proposal at ~21% Premium JPST +10.2%; Handy & Harman to Pay $11/Shr Cash for Jps HERO +8.1%; Saudi Aramco Withdraws Termination Notice for Hercules 261 Contract KTOS +7.2%; Ultra Electronics to Buy Kratos’ EPD Unit for Up to $265m Cash REGI +5.9%; Upgraded at Piper Jaffray FELP +5.6%; Energy Assumed Buy at Goldman ANR +4.3%;June 1, 2015
business
U.S. PRE-MARKET MOVERS: ANR CLD CLVS EXEL IMGN JNPR KTOS MRTXEquity movers in early trading, with shrs traded pre-mkt: Advancers: ONTY +29.5% (1558.1k); ONT-380 Data Backs Plans to Initiate Phase 2 Trial OMG +27.9% (30k); To Be Bought by Apollo for $34-Shr, Premium 28% IMGN +19.4% (57.2k); Ovarian Cancer Drug Has 53% Response Rate in Study VBLT +10.7% (268.2k); Positive Ovarian Cancer Data EXEL +12.1% (119.3k); Positive Melanoma Data at ASCO ANR +10.6% (114.7k); Assumed Neutral at Goldman TGTX +8% (11.1k); Presented at ASCO SYN +7.9% (37.1k); New OutperfoJune 1, 2015